BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Institute of Oncology
X-ORIGINAL-URL:https://www.bricbordeaux.com/en/
X-WR-CALDESC:Events for Bordeaux Institute of Oncology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230426
DTEND;VALUE=DATE:20230427
DTSTAMP:20230428T082910Z
CREATED:20230426T082749Z
LAST-MODIFIED:20230428T082910Z
UID:43220-1682467200-1682553599@www.bricbordeaux.com
SUMMARY:Financing of the PORPHYRIA project by SATT Aquitaine
DESCRIPTION:SATT Aquitaine invests in the maturation of innovative projects from regional public research. SATT Aquitaine’s objective is to mature these inventions\, from the stage of research results to pre-industrialization (proof of concept)\, and to support them until they are brought to market. \nHead by Pr Emmanuel RICHARD\, PU-PH\, head of the biochemistry department at Bordeaux University Hospital and member of theteam 08 – Biotherapies Genetics and Oncology (BioGO)in collaboration with Dr Oscar MILLET of the CICBioGUNE \, Bilbao\, the project PORPHYRIA aims to develop a pharmacological therapeutic option for erythropoietic porphyrias\, a group of rare diseases of heme metabolism. The objective of the €568\,000 investment by SATT Aquitaine is to identify and validate in-vitro and in-vivo a pharmacological inhibitor of the ALAS2 enzyme\, previously identified as a therapeutic target by the BioGO team. \nMore information at this link
URL:https://www.bricbordeaux.com/en/event/financing-of-the-porphyria-project-by-satt-aquitaine/
CATEGORIES:News
ATTACH;FMTTYPE=image/png:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2023/04/financement-satt-biogo.png
END:VEVENT
END:VCALENDAR